NKGen Biotech

NKGen Biotech Rule of 40

The Rule of 40 of NKGen Biotech (NKGN) as of Nov 22, 2026 is -31,700.11 %.

Rule of 40

-31,700.11 %

Last updated:

Rule of 40 of NKGen Biotech is 2022 -31,700.11 % . Rule of 40 of NKGen Biotech was 2021 - . It decreases by % lower compared to the previous year.

The NKGen Biotech Rule of 40 history

The NKGen Biotech Rule of 40 history
YEARRule of 40YoY
-31,700.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Rule of 40 of NKGen Biotech is -31,700.11 % in 2022.

On Eulerpool you can find the complete historical development of Rule of 40 NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — NKGen Biotech

All Key Metrics — NKGen Biotech